The concept of liquid biopsy as an analysis tool for non-solid tissue carried out for the purpose of providing information about solid tumors was introduced approximately 20 years ago. Additional to the detection of circulating tumor cells (CTCs), the liquid biopsy approach quickly included the analysis of circulating tumor DNA (ctDNA) and other tumor-derived markers such as circulating cell-free RNA or extracellular vesicles. Liquid biopsy is a non-invasive technique for detecting multiple cancer-associated biomarkers that is easy to obtain and can reflect the characteristics of the entire tumor mass. Currently, ctDNA is the key component of the liquid biopsy approach from the point of view of the prognosis assessment, prediction, and monitoring of the treatment of non-small-cell lung cancer (NSCLC) patients. ctDNA in NSCLC patients carries variants or rearrangements that drive carcinogenesis, such as those in EGFR, KRAS, ALK, or ROS1. Due to advances in pharmacology, these variants are the subject of targeted therapy. Therefore, the detection of these variants has gained attention in clinical medicine. Recently, methods based on qPCR (ddPCR, BEAMing) and next-generation sequencing (NGS) are the most effective approaches for ctDNA analysis. This review addresses various aspects of the use of liquid biopsy with an emphasis on ctDNA as a biomarker in NSCLC patients.

Department of Biology Faculty of Medicine in Pilsen Charles University Alej Svobody 1655 76 323 00 Plzen Czech Republic

Department of Histology Faculty of Medicine in Pilsen Charles University Karlovarska 48 301 66 Plzen Czech Republic

Department of Medical Chemistry and Biochemistry Faculty of Medicine in Pilsen Charles University Karlovarska 48 301 66 Plzen Czech Republic

Department of Pneumology and Phthisiology Faculty of Medicine in Pilsen Charles University University Hospital in Pilsen E Benese 13 301 00 Plzen Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc22023666

003      

CZ-PrNML

005      

20221031095120.0

007      

ta

008      

221010s2022 sz f 000 0|eng||

009      

AR

024    7_

$a 10.3390/diagnostics12081799 $2 doi

035    __

$a (PubMed)35892510

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a sz

100    1_

$a Pesta, Martin $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/76, 323 00 Plzen, Czech Republic $1 0000000181870566

245    10

$a Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer / $c M. Pesta, D. Shetti, V. Kulda, T. Knizkova, K. Houfkova, MS. Bagheri, M. Svaton, J. Polivka

520    9_

$a The concept of liquid biopsy as an analysis tool for non-solid tissue carried out for the purpose of providing information about solid tumors was introduced approximately 20 years ago. Additional to the detection of circulating tumor cells (CTCs), the liquid biopsy approach quickly included the analysis of circulating tumor DNA (ctDNA) and other tumor-derived markers such as circulating cell-free RNA or extracellular vesicles. Liquid biopsy is a non-invasive technique for detecting multiple cancer-associated biomarkers that is easy to obtain and can reflect the characteristics of the entire tumor mass. Currently, ctDNA is the key component of the liquid biopsy approach from the point of view of the prognosis assessment, prediction, and monitoring of the treatment of non-small-cell lung cancer (NSCLC) patients. ctDNA in NSCLC patients carries variants or rearrangements that drive carcinogenesis, such as those in EGFR, KRAS, ALK, or ROS1. Due to advances in pharmacology, these variants are the subject of targeted therapy. Therefore, the detection of these variants has gained attention in clinical medicine. Recently, methods based on qPCR (ddPCR, BEAMing) and next-generation sequencing (NGS) are the most effective approaches for ctDNA analysis. This review addresses various aspects of the use of liquid biopsy with an emphasis on ctDNA as a biomarker in NSCLC patients.

655    _2

$a časopisecké články $7 D016428

655    _2

$a přehledy $7 D016454

700    1_

$a Shetti, Dattatrya $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/76, 323 00 Plzen, Czech Republic $1 000000018638804X

700    1_

$a Kulda, Vlastimil $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Karlovarska 48, 301 66 Plzen, Czech Republic $1 000000017926994X

700    1_

$a Knizkova, Tereza $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/76, 323 00 Plzen, Czech Republic

700    1_

$a Houfkova, Katerina $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/76, 323 00 Plzen, Czech Republic

700    1_

$a Bagheri, Mahyar Sharif $u Department of Histology, Faculty of Medicine in Pilsen, Charles University, Karlovarska 48, 301 66 Plzen, Czech Republic $1 0000000212281300

700    1_

$a Svaton, Martin $u Department of Pneumology and Phthisiology, Faculty of Medicine in Pilsen, Charles University, University Hospital in Pilsen, E. Benese 13, 301 00 Plzen, Czech Republic

700    1_

$a Polivka, Jiri $u Department of Histology, Faculty of Medicine in Pilsen, Charles University, Karlovarska 48, 301 66 Plzen, Czech Republic

773    0_

$w MED00195450 $t Diagnostics (Basel, Switzerland) $x 2075-4418 $g Roč. 12, č. 8 (2022)

856    41

$u https://pubmed.ncbi.nlm.nih.gov/35892510 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20221010 $b ABA008

991    __

$a 20221031095118 $b ABA008

999    __

$a ind $b bmc $g 1853965 $s 1174954

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 12 $c 8 $e 20220725 $i 2075-4418 $m Diagnostics $n Diagnostics $x MED00195450

GRA    __

$a LTAUSA19080 $p Ministry of Education Youth and Sports

GRA    __

$a Cooperatio Program, research area MED/DIAG $p Ministry of Education Youth and Sports

GRA    __

$a FNPl, 00669806 $p Ministry of Health

LZP    __

$a Pubmed-20221010